Literature DB >> 10732902

Early and intermediate-term complications of self-expanding stents limit its potential application in children with congenital heart disease.

Y F Cheung1, S Sanatani, M P Leung, D G Human, A K Chau, J A Culham.   

Abstract

OBJECTIVES: We report on the early and intermediate-term follow-up results of self-expanding Wallstent (Schneider, Switzerland) implanted in children with congenital heart disease.
BACKGROUND: The inherent shortcomings of balloon-expandable stents prompted the trial of an alternative stent.
METHODS: Twenty patients underwent 22 implantations of 25 self-expanding Wallstents between December 1993 and June 1997 in two institutions. The mean age and weight were 10.8+/-4.5 years and 30.5+/-14.2 kg, respectively. The patients were divided into two groups: 1) Group I comprised 17 patients with pulmonary arterial stenoses, 2) Group II comprised four patients with venous stenoses (one belonged to both groups). Sixteen patients underwent recatheterization at a median of 5.8 months (range 0.5 to 31, mean 8.1 months) after stenting. Hemodynamic and angiographic changes after the interventional procedures and complications were documented.
RESULTS: All the stents were successfully deployed in the intended position. In Group I, the narrowest diameter of the stented vessel increased from 4.1+/-1.5 to 8+/-2 mm (95% increase, p < 0.0001) while the systolic pressure gradient across decreased from 24.6+/-15.8 to 12.1+/-11.4 mm Hg (51% decrease, p = 0.001). In Group II, the dimensional changes of the narrowest segment increased from 4.3+/-0.5 to 7.5+/-0.4 mm (75% increase, p = 0.003), and the pressure gradient reduced from 5.0+/-2.9 to 0.9+/-1.0 mm Hg (82% decrease, p = 0.04) across the stented venous channel. Distal migration of two optimally positioned stents occurred within 24 h of implantation. At recatheterization, significant neointimal ingrowth (>30% of the expanded diameter) was noted in 7 (28%) of the 25 implanted stents. This responded poorly to balloon dilation. Predisposing factors for the neointimal ingrowth included stents of smaller diameter (<9 mm) and longer period after implantation.
CONCLUSIONS: Self-expanding Wallstent could be deployed easily and safely to relieve vascular stenoses in children. The complications of distal migration, significant neointimal ingrowth and its unyielding design to overdilation limit its application to this patient group.

Entities:  

Mesh:

Year:  2000        PMID: 10732902     DOI: 10.1016/s0735-1097(99)00644-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  Biomimetic modification of metallic cardiovascular biomaterials: from function mimicking to endothelialization in vivo.

Authors:  Yajun Weng; Junying Chen; Qiufen Tu; Quanli Li; Manfred F Maitz; Nan Huang
Journal:  Interface Focus       Date:  2012-03-28       Impact factor: 3.906

2.  Palliation using a self-expandable stent in a patient with obstructive right-ventricular outflow tract after total correction of tetralogy of Fallot: self-expandable stent in tetralogy of Fallot.

Authors:  Sang-Yun Lee; Jin-Young Song; Eun-Young Choi; Jae-Suk Baek
Journal:  Pediatr Cardiol       Date:  2012-03-13       Impact factor: 1.655

3.  The role of stents in the treatment of congenital heart disease: Current status and future perspectives.

Authors:  Bjoern Peters; Peter Ewert; Felix Berger
Journal:  Ann Pediatr Cardiol       Date:  2009-01

4.  The use of anticoagulation in pediatric cardiac disease.

Authors:  J R Boris; M A Harris
Journal:  Images Paediatr Cardiol       Date:  2003-07

5.  The role of the new Valeo stent in treating pulmonary artery stenoses in children with complex cardiac malformations: A report of two cases.

Authors:  Nikhil Sharma; Sebastian Goreczny
Journal:  Am J Case Rep       Date:  2014-06-26

6.  Self-Expandable Stents in Vascular Stenosis of Moderate to Large-Sized Vessels in Congenital Heart Disease: Early and Intermediate-Term Results.

Authors:  Gi Young Jang; Kee Soo Ha
Journal:  Korean Circ J       Date:  2019-05-29       Impact factor: 3.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.